Hologic (HOLX)
(Delayed Data from NSDQ)
$73.48 USD
-0.05 (-0.07%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $73.40 -0.08 (-0.11%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HOLX 73.48 -0.05(-0.07%)
Will HOLX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HOLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOLX
Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?
3 Medical Instruments Picks to Navigate Industry Challenges
HOLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
Here's Why You Should Retain CONMED (CNMD) Stock for Now
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
Other News for HOLX
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2024 on Monday, July 29, 2024
3 Online Sports Betting Stocks That Look Like Likely Winners
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analyst Scoreboard: 7 Ratings For Hologic
Women's Health-Focused Hologic Has Significant Capacity For Expansion Via M&A, Bullish Analyst Says